7 May 2025 - The vaccine must not be used in people 65 years and above while review is underway.

The EMA’s safety committee (PRAC) has started a review of Ixchiq (a live attenuated chikungunya vaccine) following reports of serious adverse events in elderly people.

Read EMA press release